1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 29; no. suppl_8
Main Authors	Cavalli, F, Jin, J, Pylypenko, H, Verhoef, G, Siritanaratkul, N, Drach, J, Raderer, M, Mayer, J, Pereira, J, Tumyan, G, Okamoto, R, Nakahara, S, Hu, P, Appiani, C, Nemat, S, Robak, T
Format	Journal Article
Language	English
Published	Oxford University Press 01.10.2018
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdy286